ESMO Preceptorship on Immuno-Oncology Zurich November 2016

Oncology Meeting Resources

02 Nov - 03 Nov, Zurich, Switzerland

ESMO Preceptorship on Immuno-Oncology

The ESMO Preceptorship on Immuno-Oncology Zurich November 2016 was designed for understanding the basics of tumour immunology; learning about the essentials of immunotherapies and their applications in cancer medicine; learning about the status of development and clinical experience of immunotherapy in different tumour types.

Presentations of the ESMO Preceptorship on Immuno-Oncology Zurich November 2016 are available to ESMO members according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful links

Presenter Presentation title Session title
R. A. Stahel, CH Immunotherapy of Cancer Some Historical Background Historical Introduction
M. van den Broek, CH From Basic to Tumour Immunology for Oncologist Session 1 Essentials of Tumour Immunology
C. Jandus, CH Cancer Vaccines Session 1 Essentials of Tumour Immunology
L. Kandalaft, CH Adoptive T-cell Transfer Session 2 Essentials in Immunotherapies
R. A. Stahel, CH Immune Checkpoint Inhibitors NSCLC Session 3 Lung Cancer, Thoracic Cancer and Colon Cancer
A. Curioni, CH Immune Checkpoint Inhibitors in Other Thoracic Malignancies Session 3 Lung Cancer, Thoracic Cancer and Colon Cancer
T. Winder, CH Immunotherapy of GI Cancer Session 3 Lung Cancer, Thoracic Cancer and Colon Cancer
R. Dummer, CH Mono Combo Immunotherapy for Melanoma Session 4 Melanoma
J. Lim, UK Anti-PD-L1 Kept Patient at Work Session 5 Audience Cases
F. Köse, TR Pseudoprogression During Immunotherapy in a Case of Malign Melanoma Session 5 Audience Cases
S. Azevedo, PT Immunotheraphy - Case Report Session 6 Audience Cases
G. Zago, IT Atezolizumab: a New Treatment Option for NSCLC Session 6 Audience Cases
G. Curigliano, IT Breast Cancer Session 7 Clinical Development
L. Kandalaft, CH Ovarian Cancer Session 7 Clinical Development
H. Läubli, CH Functional Assessment Of Immune Responses and Identification of New Antigens Session 8 Immunomonitoring and Tumour Antigens